Fetal Aneuploidy Confirmation Testing Market Size Forecast From 2026 To 2030: Key Industry Trends
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Fetal Aneuploidy Confirmation Testing Market Forecast: Value Set To Climb From $1.58 Billion To $2.36 Billion
The fetal aneuploidy confirmation testing market size has seen rapid expansion in recent years. It is projected to grow from $1.43 billion in 2025 to $1.58 billion in 2026, at a compound annual growth rate (CAGR) of 10.4%. The historical growth can be attributed to rising maternal age pregnancies, an increasing prevalence of chromosomal abnormalities, growing awareness of prenatal screening programs, advancements in cytogenetic testing methods, and the expansion of hospital-based diagnostic laboratories.
The fetal aneuploidy confirmation testing market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.6%. This growth during the forecast period can be linked to several factors, including the wider acceptance of precision medicine strategies, the increasing incorporation of AI-powered genetic analysis tools, a heightened need for non-invasive prenatal testing confirmation, the proliferation of genomic research projects, and increased funding for healthcare infrastructure in developing economies. Key developments expected within this period involve the greater uptake of next-generation sequencing technologies, an elevated requirement for prompt and precise prenatal diagnosis, a stronger inclination towards confirmatory diagnostic testing following positive screening results, the extended application of advanced chromosomal microarray analysis, and an expanding supply of specialized prenatal diagnostic services.
Get A Free Sample Report With In-Depth Market Insights:
Fetal Aneuploidy Confirmation Testing Market Growth Factors Behind Sustained Expansion
The increasing age at which women become mothers is projected to fuel the expansion of the fetal aneuploidy confirmation testing market. Maternal age refers to a woman’s age when she becomes pregnant or gives birth. This age is on the rise as women often postpone starting families to advance their education and careers. Fetal aneuploidy confirmation testing plays a crucial role in mitigating the risks linked to older maternal age by precisely identifying chromosomal abnormalities, which are more prevalent in pregnancies among older women, enabling prompt medical advice and well-informed choices regarding pregnancy. For example, data from June 2025, from the US-based government agency, the Centers for Disease Control and Prevention, showed that the average age of mothers at their first birth rose from 27.4 years in 2022 to 27.5 years in 2023, marking an increment of 0.1 years. Consequently, the rising maternal age is a key factor boosting the growth of the fetal aneuploidy confirmation testing market.
Fetal Aneuploidy Confirmation Testing Market Segment Outlook: Which Categories Are Growing Fastest?
The fetal aneuploidy confirmation testing market covered in this report is segmented –
1) By Test Type: Non-Invasive Prenatal Testing, Invasive Testing, Other Test Types
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Microarray, Other Technologies
3) By Application: Trisomy, Sex Chromosome Aneuploidy, Microdeletions, Other Applications
4) By End-User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Other End Users
Subsegments:
1) By Non-Invasive Prenatal Testing: Cell-Free Fetal Deoxyribonucleic Acid Testing, Maternal Serum Screening, Ultrasound-Based Risk Assessment, Next-Generation Sequencing-Based Non-Invasive Prenatal Testing, Chromosomal Microarray Analysis
2) By Invasive Testing: Amniocentesis, Chorionic Villus Sampling, Cordocentesis, Fetal Biopsy, Fetal Karyotyping
3) By Other Test Types: Preimplantation Genetic Testing, Targeted Gene Panels, Multiplex Polymerase Chain Reaction Testing, Fluorescence In Situ Hybridization Testing, Comparative Genomic Hybridization Testing
Fetal Aneuploidy Confirmation Testing Market Leading Players And Competitive Positioning
Major companies operating in the fetal aneuploidy confirmation testing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., SYNLAB AG, Myriad Genetics Inc., CapitalBio Technology Co. Ltd., BGI Genomics Co. Ltd., Centogene N.V., Yourgene Health plc, MedGenome Labs Ltd., Fulgent Genetics Inc., Annoroad Gene Technology Co. Ltd., CeGaT GmbH, LifeCodexx AG, Variantyx Inc., Igenomix S.L.U.
View The Full Fetal Aneuploidy Confirmation Testing Market Report:
Fetal Aneuploidy Confirmation Testing Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the fetal aneuploidy confirmation testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fetal aneuploidy confirmation testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
